October 2024 – Collagen Solutions, a premier global supplier, developer, and manufacturer of engineered biomaterial-based medical devices and components with applications in regenerative medicine, has agreed to be acquired by RTI Surgical (“RTI”), a leading contract development and manufacturing organization (“CDMO”) in tissue engineering for regenerative medicine. RTI is a portfolio company of Montagu Private Equity (“Montagu”), a leading Europe and U.S.-based private equity firm with $12 billion of assets under management. England & Company served as the exclusive financial advisor to Collagen Solutions in this transaction.
“The England & Company team are experts in medical device marketing and contract manufacturing, with extensive relationships in the biomaterials and regenerative medicine spaces. They found us the ideal partner for this business and negotiated strong terms for us,” said Rick Mulford, CEO of Collagen Solutions.
Collagen Solutions provides its OEM customers with high-quality components and fully assembled devices made from medical-grade collagen and xenograft tissue. These devices are used in various therapeutic areas, including cardiovascular, wound care, orthopedics and sports medicine, dental, biosurgery, and neurosurgery. The Company is based in Eden Prairie, MN, and has additional strategically located manufacturing sites in the U.K., New Zealand, and Glencoe, MN.
RTI’s acquisition of Collagen Solutions will broaden RTI’s soft tissue portfolio by leveraging Collagen Solutions’ proficiency in bovine and porcine collagen materials. This transaction will also facilitate access to rapidly growing therapeutic fields, and it has the potential to expedite the creation of pioneering biomaterials with combination products and improve patient outcomes.
“Collagen Solutions is an excellent strategic fit for RTI Surgical, bringing specialized and complementary capabilities and expertise in soft tissue engineering,” said Olivier Visa, President and Chief Executive Officer, RTI Surgical.
Adrien Sassi, Partner at Montagu, added, “Supporting patient care by helping to bring clinically differentiated solutions to market in a fast and reliable way is at the core of RTI’s mission, and the acquisition of Collagen Solutions is a transformative step in this journey. It reinforces RTI’s ability to partner strategically with OEMs from early product development to full-scale commercialization, including in clinical applications facing unmet patient needs like structural heart and tissue reconstruction.”
About Collagen Solutions
Collagen Solutions is a global supplier, developer, and manufacturer of medical-grade collagen, tissues, and other biomaterials for use in regenerative medicine, medical devices, and research. The Company’s expertise includes developing and manufacturing engineered tissue scaffolds and other biomaterials-based medical devices. These products are used in various applications, including cardiovascular, dental, orthopedics, neurosurgery, wound healing and biosurgery, and research. For more information, please visit: www.collagensolutions.com.
About RTI Surgical
RTI Surgical is a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine. It serves as an expert partner to OEMs (Original Equipment Manufacturers), working with them to identify clinical problems and develop customized solutions that promote healing, accelerate recovery, and help prevent complications. Using RTI’s extensive portfolio of biological materials, it focuses on specialized clinical segments, including plastic and reconstructive surgery, sports medicine and orthopedics, cardiac, and neuro and spine surgery. Headquartered in Alachua, Florida, RTI has manufacturing facilities in the United States and Europe. Montagu acquired RTI in a carve-out acquisition in July 2020. For more information, visit www.rtisurgical.com.